Indeed, several glycolytic enzymes are deregulated in human breast cancer, including PKM2 (pyruvate kinase muscle isozyme 2) [37], PFK (phosphofructokinase) [38,39], and HK2 (hexokinase 2) [40,41], and the pharmacological inhibition of HK2 has been investigated as a therapeutic strategy [42]. This evidence concerns the gene HK2 and breast carcinoma.